FOUNDATION FIGHTING BLINDNESS
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1974-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.ffb.ca/
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)β’ Click on a phase to view related trials
Inherited Retinal Degenerative Disease Registry
- Conditions
- Eye Diseases HereditaryChoroideremiaCongenital Stationary Night BlindnessEnhanced S-Cone SyndromeGoldmann-Favre SyndromeRefsum SyndromeRetinoschisisRod-Cone DystrophyBatten DiseaseChoroidal Dystrophy
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Foundation Fighting Blindness
- Target Recruit Count
- 20000
- Registration Number
- NCT02435940
- Locations
- πΊπΈ
Foundation Fighting Blindness, Columbia, Maryland, United States
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
- Conditions
- Stargardt Disease
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Foundation Fighting Blindness
- Target Recruit Count
- 259
- Registration Number
- NCT01977846
- Locations
- πΊπΈ
Greater Baltimore Medical Center, Baltimore, Maryland, United States
πΊπΈWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, United States
πΊπΈCole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
Trial of Oral Valproic Acid for Retinitis Pigmentosa
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Foundation Fighting Blindness
- Target Recruit Count
- 90
- Registration Number
- NCT01233609
- Locations
- πΊπΈ
University of Miami, Bascom Palmer Eye Institute, Miami, Florida, United States
πΊπΈUniversity of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
πΊπΈOregon Health & Science University, Portland, Oregon, United States
News
FDA Grants Breakthrough Therapy Designation to Nacuity's NPI-001 for Retinitis Pigmentosa Treatment
The U.S. FDA has granted Breakthrough Therapy Designation to NPI-001 (N-acetylcysteine amide) tablets, developed by Nacuity Pharmaceuticals for treating retinitis pigmentosa, a serious inherited blinding disease.
ARPA-H Funds Multi-Institutional Consortium to Cure Blindness Through Eye Transplantation
The University of Colorado Anschutz Medical Campus will receive up to $46 million from ARPA-H to advance vision-restoring human whole eye transplantation.
Foundation Fighting Blindness Launches Natural History Study for Usher Syndrome Type 3
The Foundation Fighting Blindness is initiating a natural history study for Usher syndrome type 3 (USH3) to track vision and hearing changes.
Free Genetic Testing Initiative Accelerates Drug Development for Inherited Retinal Diseases
The Foundation Fighting Blindness's My Retina Tracker program offers free genetic testing and counseling for inherited retinal disease patients in the US, having enrolled over 6,000 participants since 2017.